Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIADNE neoadjuvant trastuzumab deruxtecan trial in HER2-positive breast cancer
2022-501504-95-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Apr 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of trastuzumab deruxtecan, trastuzumab, pertuzumab, docetaxel, carboplatin and 6 more in breast cancer (5 arms), sponsored by Karolinska University Hospital. Primary endpoint: Pathologic complete response in molecularly HER2-enriched population. Planned start Apr 2023; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-501504-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501504-95-00.